Author Correction: In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Phase 1 Trial of In Vivo Base-Editing Gene Therapy for Heterozygous Familial Hypercholesterolemia

  • By

  • Ping Wan

  • Siyuan Tang

  • Dongni Lin

  • Yuming Lu

  • Mei Long

  • Ling Xiao

  • Yanhong Jiang

  • Jiaoyang Liao

  • Xiaoying Ma

  • Ying Liu

  • Wensu Yu

  • Michael Ott

  • Zi Jun Wang

  • Yuxuan Wu

  • Taihua Yang

  • Qiang Xia

  • November 3, 2026

Share

  • 1

    A correction published online March 3, 2026, amended Table 1 and Extended Data Fig. 2d in the phase 1 trial report.

  • 2

    A unit-conversion transcription error had placed ApoB and ApoA1 baseline measurements against the neighboring non-HDL-C and HDL-C rows.

  • 3

    Corrected ApoB measurements for Patients 1–6 were 164, 165, 119, 115, 104, and 171 mg/dL, respectively.

  • 4

    Corrected ApoA1 measurements for Patients 1–6 were 159, 174, 117, 157, 140, and 192 mg/dL, respectively.

  • 5

    Extended Data Fig. 2d and its source data now show net background-corrected A-to-G editing values; the corrections did not affect the article’s conclusions, results, or safety and efficacy assessments

Original Source(s)

Author Correction: In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial

  • by Ping Wan, Siyuan Tang, Dongni Lin, Yuming Lu, Mei Long, Ling Xiao, Yanhong Jiang, Jiaoyang Liao, Xiaoying Ma, Ying Liu, Wensu Yu, Michael Ott, Zi Jun Wang, Yuxuan Wu, Taihua Yang, Qiang Xia

  • November 3, 2026

Related Content

Neighborhood Disadvantage and Unequal Detection of Atrial Fibrillation

Mortality score may refine heart allocation

A laboratory- and device-based model outperformed the current 6-status system in predicting short-term mortality among heart transplant candidates.

FDA adds generic valganciclovir oral solution

 The new option is indicated for CMV prophylaxis in pediatric kidney and heart transplant recipients, as well as adult CMV retinitis and transplant prophylaxis.